Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neuro-Oncology

• Publication date

  2015-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/neuonc/nov299PMID 26681765PMCID PMC4864261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteasome inhibitors in cancer therapy

  2017cited by this paper
• Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models

  2014cited by this paper
• TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth

  2013cited by this paper
• CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

  2013cited by this paper
• Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)

  2013cited by this paper
• Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis

  2013cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Novel proteasome inhibitors to overcome bortezomib resistance.

  2011cited by this paper
• Proteasome inhibitors in cancer therapy

  2011cited by this paper
• Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.

  2011cited by this paper
• Neural Stem/Progenitors and Glioma Stem-Like Cells Have Differential Sensitivity to Chemotherapy

  2011influential reference
• Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma

  2011cited by this paper
• Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

  2010cited by this paper
• Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.

  2010cited by this paper
• Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI‐0052 (marizomib) in a human plasmacytoma xenograft murine model

  2010cited by this paper
• In vivo imaging, tracking, and targeting of cancer stem cells.

  2009cited by this paper
• Hypoxia and HIF1α Repress the Differentiative Effects of BMPs in High‐Grade Glioma

  2009cited by this paper
• Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.

  2008cited by this paper
• Targeting proteasomes as therapy in multiple myeloma.

  2008cited by this paper
• Molecular Cancer BioMed Central

  2008cited by this paper
• Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells

  2008cited by this paper
• Mechanisms of proteasome inhibitor action and resistance in cancer.

  2008cited by this paper
• NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.

  2007influential reference
• Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype.

  2007cited by this paper
• Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

  2006cited by this paper
• Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.

  2006cited by this paper
• Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

  2006cited by this paper
• NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model

  2006cited by this paper
• Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib

  2006cited by this paper
• Study of brain and whole blood PK/PD of bortezomib in rat models.

  2006cited by this paper
• Phase I trial of bortezomib in adults with recurrent malignant glioma.

  2006cited by this paper
• Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)

  2005cited by this paper
• Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

  2004cited by this paper
• Regulation of apoptosis: the ubiquitous way

  2003cited by this paper
• Isolation and characterization of neural progenitor cells from post‐mortem human cortex

  2003cited by this paper
• Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells

  2003cited by this paper
• Membrane properties of rat embryonic multipotent neural stem cells

  2003cited by this paper
• Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells*

  2003cited by this paper
• Brain-tumour drug resistance: the bare essentials.

  2002cited by this paper
• Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

  2002cited by this paper
• The ubiquitin‐mediated proteolytic pathway: Mode of action and clinical implications

  2000cited by this paper
• Temozolomide and treatment of malignant glioma.

  2000cited by this paper
• Proteasome Inhibition: a New Strategy in Cancer Treatment

  2000cited by this paper

• Dysregulation of post-translational modifications in glioma: advances in pathological mechanisms and clinical targeting strategies

  2026cites this paper
• Dual targeting of the mitochondrial Lon peptidase 1 and the chymotrypsin-like proteasome activity as a potential therapeutic strategy in malignant astrocytoma models.

  2025cites this paper
• Structural insights into Salinosporamide A mediated inhibition of the human 20S proteasome

  2025cites this paper
• Exploring the in vitro and in vivo antileishmanial potential of Marizomib against Leishmania amazonensis and Leishmania infantum

  2025cites this paper
• Marizomib in the therapy of brain tumors—how far did we go and where do we stand?

  2025influential citation
• Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity.

  2025cites this paper
• Targeting ubiquitination in disease and therapy

  2025cites this paper
• Development of Macrocyclic Peptide-Based Proteasome Inhibitors with Enhanced Blood-Brain Barrier Penetration for Treating Brain Neoplasms.

  2025cites this paper
• MG132 induces cell type‑specific anticancer effects in uterine leiomyosarcoma cell lines

  2025cites this paper
• New Targets, New Agents, and Radiotherapy: Primary Brain Tumors

  2025cites this paper
• Structural Insights into Salinosporamide a Mediated Inhibition of the Human 20S Proteasome

  2025cites this paper
• From Deep-Sea Natural Product to Optimized Therapeutics: Computational Design of Marizomib Analogs

  2025cites this paper
• Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review

  2024cites this paper
• Targeting FUS-ALS aggregation with Proteasome Inhibitors

  2024cites this paper
• NF-κB in biology and targeted therapy: new insights and translational implications

  2024cites this paper
• Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies

  2024cites this paper
• The proteasome as a drug target for treatment of parasitic diseases.

  2024cites this paper
• Structural elucidation of recombinant Trichomonas vaginalis 20S proteasome bound to covalent inhibitors

  2024cites this paper
• Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

  2024cites this paper
• IgG-k/IgG-λ Para-Osseous Plasmacytoma Relapsed as Soft-Tissue Plasmacytoma with IgA-k Immunophenotype: A Case Report and Review of the Literature on Related Biochemical Aspects

  2024cites this paper
• The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells

  2024influential citation
• Antiproliferative metabolites against glioma cells from the marine-associated actinomycete Streptomyces sp. ZZ735.

  2024cites this paper
• Marizomib (Salinosporamide A) Promotes Apoptosis in A375 and G361 Melanoma Cancer Cells

  2024cites this paper
• Proteasome inhibition for glioblastoma: lessons learned and new opportunities.

  2024cites this paper
• The Proteasome Inhibitor CEP-18770 Induces Cell Death in Medulloblastoma

  2024cites this paper
• Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma

  2023cites this paper
• Dual targeting of mitochondrial Lon peptidase 1 and chymotrypsin-like protease by small molecule BT317, as potential therapeutics in malignant astrocytoma

  2023cites this paper
• Discovery and Validation of Novel LonP1 and Proteasome Inhibitor in IDH1-R132H Malignant Astrocytoma Models

  2023cites this paper
• Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in embryonal tumors with multilayered rosettes

  2023cites this paper
• Shikimate-Derived Meroterpenoids from the Ascidian-Derived Fungus Amphichorda felina SYSU-MS7908 and Their Anti-Glioma Activity.

  2023cites this paper
• Multiple Myeloma in 2023 Ways: From Trials to Real Life

  2023cites this paper
• Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine

  2023influential citation
• Advances in research on potential inhibitors of multiple myeloma.

  2023cites this paper
• Proteasome inhibition protects blood–brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer’s disease model

  2023cites this paper
• Fabrication of marizomib-loaded zeolitic imidazolate framework-8@manganese dioxide for promising drug delivery system of glioma cancer cells

  2023cites this paper
• Structural elucidation of recombinant Trichomonas vaginalis 20S proteasome bound to covalent inhibitors

  2023cites this paper
• The role of proteasomes in tumorigenesis

  2023cites this paper
• Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics

  2023cites this paper
• Targeting mitochondrial energetics reverses panobinostat‐ and marizomib‐induced resistance in pediatric and adult high‐grade gliomas

  2023cites this paper
• LonP1 Drives Proneural Mesenchymal Transition in IDH1-R132H Diffuse Glioma

  2023cites this paper
• Novel fabrication of marizomib-loaded chitosan-coated hydroxyapatite nanocarriers as a promising system for effective treatment of ovarian cancer

  2022cites this paper
• Molecular targeted therapy: A new avenue in glioblastoma treatment.

  2022influential citation
• Multiple myeloma with isolated central nervous system relapse after autologous stem cell transplantation: A case report and review of the literature

  2022cites this paper
• Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma

  2022cites this paper
• Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo

  2022cites this paper
• The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression

  2022cites this paper
• Glioblastoma: Current Status, Emerging Targets, and Recent Advances

  2022cites this paper
• Secondary CNS myeloma with remission after systemic CNS-penetrating agents

  2022cites this paper
• Advances in the treatment of extramedullary disease in multiple myeloma

  2022cites this paper
• Therapeutic Options in Neuro-Oncology

  2022cites this paper
• Mono- and Dimeric Xanthones with Anti-Glioma and Anti-Inflammatory Activities from the Ascidian-Derived Fungus Diaporthe sp. SYSU-MS4722

  2022cites this paper
• 6 Intramedullary Spinal Cord Tumors: Current Research and Potential Therapeutics

  2022cites this paper
• Synthesis and psychotropic activity of a series of 4-aminopyroglutamates

  2022cites this paper
• Streptonaphthyridine A, a new naphthyridine analogue with antiproliferative activity against human glioma cells from mariana trench-associated actinomycete Streptomyces sp. SY2111

  2021cites this paper
• Pten Deficiency Leads To Proteasome Addiction, A Novel Vulnerability In Glioblastoma.

  2021cites this paper
• Recent insight into the role of RING-finger E3 ligases in glioma.

  2021cites this paper
• Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

  2021cites this paper
• Application of marine natural products in drug research.

  2021cites this paper
• Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.

  2021cites this paper
• The role of the ubiquitin proteasome system in glioma: analysis emphasizing the main molecular players and therapeutic strategies identified in glioblastoma multiforme.

  2021cites this paper
• Clinical pharmacology differences among proteasome inhibitors: implications for their use in clinical practice.

  2021cites this paper
• A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials

  2021cites this paper
• Marine Streptomyces sp. Isolated From the Brazilian Endemic Tunicate Euherdmania sp. Produces Dihydroeponemycin and Analogs With Potent Antiglioma Activity

  2021cites this paper
• Exploring the role and clinical implications of proteasome inhibition in medulloblastoma

  2021cites this paper
• Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist

  2021cites this paper
• The Evolving Role of Targeted Therapies in Primary Central Nervous System Tumors

  2021cites this paper
• The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

  2021cites this paper
• Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress

  2021cites this paper
• Research progress in proteasome inhibitor resistance to multiple myeloma.

  2021cites this paper
• Investigational new drugs against glioblastoma

  2021cites this paper
• Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell cultures

  2021cites this paper
• On the Origin of the Different Reversible Characters of Salinosporamide A and Homosalinosporamide A in the Covalent Inhibition of the Human 20S Proteasome

  2021cites this paper
• Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data

  2021cites this paper
• Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors

  2021cites this paper
• Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers

  2021cites this paper
• Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma

  2021cites this paper
• Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape

  2021cites this paper
• Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts

  2021cites this paper
• Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures

  2021cites this paper
• Proteasome Inhibitor Drugs.

  2020cites this paper
• Old and new generation proteasome inhibitors in multiple myeloma.

  2020cites this paper
• Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma

  2020cites this paper
• Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy

  2020cites this paper
• Functionalized graphene oxide against U251 glioma cells and its molecular mechanism.

  2020cites this paper
• Proteasome inhibition for the treatment of glioblastoma

  2020cites this paper
• New Antifungal Metabolites from the Mariana Trench Sediment-Associated Actinomycete Streptomyces sp. SY1965

  2020cites this paper
• A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.

  2020cites this paper
• The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.

  2020cites this paper
• Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

  2020cites this paper
• New drugs in early development for treating multiple myeloma: all that glitters is not gold

  2020cites this paper
• Bioactive Metabolites from the Mariana Trench Sediment-Derived Fungus Penicillium sp. SY2107

  2020cites this paper
• The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

  2020cites this paper
• Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

  2020cites this paper
• Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance

  2020cites this paper
• Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling.

  2020cites this paper
• The role of ubiquitination in tumorigenesis and targeted drug discovery

  2020cites this paper
• Enzymatic activity of extracellular circulating proteasome in the CSF of patients with malignant intrinsic and metastatic brain tumors: proof of concept.

  2020cites this paper
• DNA inhibitors for the treatment of brain tumors

  2020cites this paper
• Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease

  2020cites this paper
• How we manage Bing–Neel syndrome

  2019cites this paper